This guidance represents the view of NICE, which was arrived at after careful consideration of the evidence available. Healthcare professionals are expected to take it fully into account when exercising their clinical judgement. However, the guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.
You can download the following documents from www.nice.org.uk/TA182 • The NICE guidance (this document).
• A quick reference guide -the recommendations.
• 'Understanding NICE guidance' -a summary for patients and carers.
• Details of all the evidence that was looked at and other background information.
For printed copies of the quick reference guide or 'Understanding NICE guidance', phone NICE publications on 0845 003 7783 or email publications@nice.org.uk and quote:
• N2012 (quick reference guide) • N2013 ('Understanding NICE guidance').
This guidance represents the view of NICE, which was arrived at after careful consideration of the evidence available. Healthcare professionals are expected to take it fully into account when exercising their clinical judgement. However, the guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.
Implementation of this guidance is the responsibility of local commissioners and/or providers. Commissioners and providers are reminded that it is their responsibility to implement the guidance, in their local context, in light of their duties to avoid unlawful discrimination and to have regard to promoting equality of opportunity. Nothing in this guidance should be interpreted in a way which would be inconsistent with compliance with those duties.
Guidance

Prasugrel in combination with aspirin is recommended as an option
for preventing atherothrombotic events in people with acute coronary syndromes having percutaneous coronary intervention, only when:
• immediate primary percutaneous coronary intervention for ST-segment-elevation myocardial infarction is necessary or
• stent thrombosis has occurred during clopidogrel treatment or
• the patient has diabetes mellitus.
1.2
People currently receiving prasugrel for treatment of acute coronary syndromes whose circumstances do not meet the criteria in 1.1
should have the option to continue therapy until they and their clinicians consider it appropriate to stop. 
2.2
According to the SPC, prasugrel should be started with a single 60-mg loading dose and then continued at 10 mg once a day for up to 12 months. Prasugrel should be used with caution in patients at increased risk of bleeding, especially in patients who are 75 years or older, people with a tendency to bleed or with body weight less than 60 kg. For full details of side effects and contraindications, see the SPC.
2.3
The manufacturer stated in its submission that the cost of both 5 mg and 10 mg tablets of prasugrel is £47.56 for a pack of 
The manufacturer's submission
The Appraisal Committee (appendix A) considered evidence submitted by the manufacturer of prasugrel and a review of this submission by the Evidence Review Group (ERG; appendix B).
3.1
Clinical evidence in the manufacturer's submission was taken from a randomised double-blind trial, TRITON-TIMI 38, that compared prasugrel with clopidogrel in 13,608 patients with moderate-to high-risk acute coronary syndromes (unstable angina, ST-segmentelevation myocardial infarction [MI] or non-ST-segment-elevation MI) who were scheduled to have percutaneous coronary intervention. Patients were given aspirin (at a recommended daily dose of between 75 and 162 mg) in combination with the drugs studied. Patients were randomised to receive a loading dose of 60 mg prasugrel followed by 10 mg prasugrel daily or a loading dose of 300 mg clopidogrel followed by 75 mg clopidogrel daily for up to 15 months (the median treatment period was 14.5 months).
After percutaneous coronary intervention, patients received daily maintenance doses of placebo tablets matched to clopidogrel or prasugrel.
3.2
The primary efficacy endpoint was a composite of the rate of nonfatal MI, non-fatal stroke or death from cardiovascular causes, during the entire follow-up period. A range of secondary composite endpoints was also included. Major safety endpoints included thrombolysis in myocardial infarction (TIMI) major bleeding not related to coronary artery bypass graft (CABG), non-CABG-related TIMI life-threatening bleeding, and TIMI major bleeding (a fall in haemoglobin of 5 g/100 ml or more) or minor bleeding (a fall in haemoglobin of 3 to less than 5 g/100 ml).
3.3
The intention-to-treat analysis of the 13,608 patients enrolled in the TRITON-TIMI 38 trial (as reported in the main trial publication)
showed that the primary efficacy endpoint was reached in 9 prasugrel was assumed to be the same as for clopidogrel (£2619), rather than using the lower weighted average from data collected in the trial (£2530).
3.15
The manufacturer identified two errors in its model after the ERG had concluded its critique of the manufacturer's submission. Unless stated otherwise, the results presented below are based on updated analyses from the manufacturer. 
3.18
The ERG stated that the TRITON-TIMI 38 trial used in the manufacturer's submission had followed robust methods and was suitably powered to show a clinically significant difference in the primary efficacy endpoint between the treatment groups.
Appropriate specified subgroup analyses and post hoc exploratory analyses were carried out. However, the ERG noted that there was per QALY gained for the target population.
3.21
The ERG advised that interpretation of the ICERs presented in the manufacturer's submission was dependent on the full acceptance of the manufacturer's assumptions about long-term mortality projections.
3.22
The ERG stated that the following key uncertainties in the underlying clinical evidence had not been addressed by its exploratory analyses:
• The extent to which patients in the trial would have benefited clinically (through reduced MIs) from a higher loading dose and pretreatment with clopidogrel was uncertain.
• Practice in the TRITON-TIMI 38 trial did not reflect the growing trend in England and Wales for percutaneous coronary intervention to be performed by radial artery access. The ERG referred to evidence that major bleeding rates are reduced when percutaneous coronary intervention is performed by this route.
• As incremental health gains for prasugrel compared with clopidogrel were small, the resulting ICERs were highly sensitive to changes in the relative benefits of prasugrel and clopidogrel.
3.23
In response to consultation on the preliminary guidance, the manufacturer provided further results from its economic model. Its analyses were intended to reflect the exploratory analysis conducted by the ERG (section 3.19), but using the whole licensed population, rather than using the typical/median patient profile available within its model. Exploratory analysis using alternative utility data, while also reducing the incidence of non-fatal recurrent Although the Committee was aware that the SPC for prasugrel stated that proton pump inhibitors could be used with prasugrel and of statements received from the manufacturer during consultation that antiplatelet activity of prasugrel was not significantly affected by the use of a specific proton pump inhibitor, it was mindful that prasugrel had not been extensively studied with a range of proton pump inhibitors and that it may be too soon to dismiss similar coprescribing concerns. The Committee concluded that, on balance, concomitant clopidogrel and proton pump inhibitor use was predominantly a prescribing issue and therefore it was most appropriately addressed between the patient and their healthcare professional on an individual basis.
4.13
The Committee also discussed patients not included in the manufacturer's target population (patients aged 75 years or older and patients whose weight was below 60 kg). The Committee noted that a lower maintenance dose of 5 mg prasugrel was specified in the marketing authorisation for these patients, but that the evidence for treating these patients with prasugrel at the reduced dose in preference to clopidogrel was limited. The
Committee agreed that the evidence was weak, but was not persuaded that the recommendations should differentiate between those included or not included in the target population.
Cost effectiveness
4.14 Bearing in mind its considerations on clinical effectiveness, the Committee, when considering the cost-effectiveness data, agreed • Costing report and costing template to estimate the savings and costs associated with implementation.
Implementation
):
• Audit support for monitoring local practice.
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Recommendations for further research • Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events. NICE technology appraisal guidance.
Publication expected September 2010.
• Acute coronary syndromes: the management of unstable angina and non-ST-segment-elevation myocardial infarction. NICE clinical guideline.
Publication expected February 2010. 
